Targeted therapy for right-sided advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a targeted drug (anti-EGFR) to chemotherapy helps people with right-sided advanced colorectal cancer whose tumors have certain gene markers. It may offer a more personalized treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with adenocarcinoma of the colon, and the tumor is on the right side.
- Your cancer is advanced (has spread or cannot be removed by surgery).
- Your tumor does not have a RAS mutation (or it has not been tested yet).
- You have not had chemotherapy for this cancer before.
- You have not been treated with an anti-EGFR drug before.
- You are healthy enough to receive combination chemotherapy plus an anti-EGFR drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.